Cancer testing laboratory Genoptix is being acquired by NeoGenomics, another cancer-focused genetic testing business, for $125 million in cash and 1 million NeoGenomics shares.
The buyout comes almost two years after Carlsbad, CA-based Genoptix was bought from Novartis (NYSE: NVS) by a pair of private investment firms, Ampersand Capital Partners and 1315 Capital, and a management group for an undisclosed sum in January 2017. Joseph Limber became the CEO of the company. Limber previously held roles at Prometheus Pharmaceuticals in San Diego, which sold to Nestlé Health Science, and Gradalis, a Dallas-based life sciences startup.
Genoptix specializes in hematology… Read more »
UNDERWRITERS AND PARTNERS